Skip to main content

NEW RELEASE:  Eurofins Viracor BioPharma Launches PanCancerIQ Comprehensive Genomic Profiling Service to Advance Precision Oncology Clinical Research and Drug Development

March 10, 2021 Lee’s Summit, MO. – Eurofins Viracor BioPharma Services, a global leader in specialty bioanalytical testing services, announces the launch of their new PanCancerIQ genomic profiling test; a next-generation sequencing (NGS) service that enables comprehensive genomic profiling of tumor samples. In addition to expanding Eurofins Viracor’s footprint in oncology clinical trial testing, the assay supports the identification of all relevant DNA and RNA variants implicated in all solid tumors. The Eurofins Viracor new PanCancerIQ assay service uses Illumina’s TruSight Oncology 500 (TSO500) NGS technology and bioinformatics, combined with clinical interpretation through utilization of a knowledgebase developed by MD Anderson Cancer Center via a partnership with Philips. The technology enables genomic characterization across a broad range of tumor types through the identification of variations and mutations in DNA and RNA in biopsy samples. The assay provides reliable results for all relevant genomic biomarkers, including universal markers such as TMB, MSI and NTRK-fusions contributing to sample consolidation, reducing patient re-biopsy, as well as potentially increasing assignment of targeted therapy. According to Viracor’s Director of Oncology Diagnostics, Karina Eterovic, PhD., “The PanCancerIQ assay, combined with our broader analytical testing solutions, can help accelerate precision oncology studies by screening patients for recruitment in genomically informed trials, unveiling potential new markers of resistance or response to new drugs currently in biopharma pipelines, and monitoring tumor molecular evolution upon recurrence or metastasis. This broader genomic analysis can also identify unknown mutations and co-mutations in specific types of cancer by screening hundreds of emerging biomarkers in addition to biomarkers in NCCN and ESMO guidelines, says Dr. Eterovic. This new service, together with the expertise at Eurofins Viracor, will enable rapid delivery of valuable NGS data to help sponsors advance biomarker programs and accelerate the development of new precision oncology treatments. The PanCancerIQ panel will also be offered for liquid biopsies (cfDNA) in late 2021, expanding the oncology portfolio for biopharma by enabling studies where tissue biopsies might not be an option. 


About Eurofins Viracor BioPharma Services Eurofins Viracor BioPharma Services, Inc., a subsidiary of Eurofins Scientific, is a trusted provider of drug development solutions to pharmaceutical and contract research organizations. We offer complex/esoteric testing and assay development, to help advance Phase 1-4 clinical trials through trusted partnership, scientific excellence, and exceptional service. For more than 30 years, Eurofins Viracor has been dedicated to helping clients advance new therapies to market by providing high quality, accurate results to evaluate the effects of drug candidates across all major therapeutic categories. We offer broad experience in molecular infectious disease testing, vaccine safety and efficacy assessment, immunogenicity, cell-based assays, allergy/hypersensitivity, and biomarker analysis. Our validated test list numbers more than 3000, with new custom assays developed on a continual basis, in response to client needs.
About Eurofins – the global leader in bio-analysis Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialized by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly qualified staff. Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods. As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP). Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity. 

Back to top